Evaluation of Tolerance and Quality of Life in Patients With Neuroendocrine Tumors Treated With Oral Anti-Tumor Drugs Within a Therapeutic Education Program (ETP-NET)

Civil Hospices of Lyon

Status: Not yet enrolling

Conditions: Oral Anti-Tumor Drugs; Therapeutic Education Program; Neuroendocrine (NE) Tumors

Treatments: Other: Questionnaires

Study type: Observational

Funder types: Other

Identifiers

NCT07258810

69HCL25_0703

2025-A01985-44 (Other Identifier)

Details and patient eligibility

About

In recent years, the arrival of targeted oral therapies has greatly changed cancer treatment. These therapies help patients stay independent by reducing the number of hospital visits, since the treatment is given at home. However, this way of giving treatment brings specific challenges, especially in managing side effects and making sure patients follow their treatment properly.

Because of this, many patient education programs have been created to help patients learn how to manage their treatment on their own. Although only a few studies have formally looked at how useful these programs are, the available information suggests that they help patients handle side effects better and follow their treatment more closely.

Neuroendocrine tumors are a diverse group of tumors that are becoming more common. More patients with these tumors are now treated with targeted oral therapies such as everolimus, sunitinib, cabozantinib, or chemotherapy with temozolomide and capecitabine.

These treatments are often given together with a patient education program. However, so far, no study has specifically looked at how helpful these education programs are for this group of patients.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patient (>18 years) at the time of the study
• Patient diagnosed with a neuroendocrine tumor (NET) with an indication for treatment with oral anti-tumor agents (everolimus, sunitinib, cabozantinib, temozolomide +/- capecitabine, others including lenvatinib)
• Collection of the patient's non-opposition to participate in the study

Exclusion criteria

• Minors
• Pregnant, parturient, or breastfeeding women
• Persons deprived of liberty by judicial or administrative decision
• Adults under legal protection measures (guardianship, conservatorship)
• Refusal to participate in the study

Trial design

100 participants in 2 patient groups

Patients enrolled in the therapeutic education program

Description:

Patient with a neuroendocrine tumor requiring treatment with oral antitumor therapy

Treatment:

Other: Questionnaires

Patients not enrolled in the therapeutic education program

Description:

Patient with a neuroendocrine tumor requiring treatment with oral antitumor therapy

Treatment:

Other: Questionnaires